Supportive care for thrombocytopenia in patients receiving treatment for myelodysplasia: a challenge for the future

References

• Greenberg PL, Garcia-Manero G, Moore M, . A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma 2013;54:XXX–XXX.
   Google Scholar
• Hirai H, Shimazaki C, Yamagata N, . Effects of thrombopoietin (c-mpl ligand) on growth of blast cells from patients with transient abnormal myelopoiesis and acute myeloblastic leukemia. Eur J Haematol 1997;59:38–46.
   PubMed Web of Science ®Google Scholar
• Corazza F, Hermans C, D'hondt S, . Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia. Blood 2006;107:2525–2530.
   PubMed Web of Science ®Google Scholar
• Fontenay-Roupie M, Dupont JM, Picard F, . Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia. Leuk Res 1998;22:527–535.
   PubMed Web of Science ®Google Scholar
• Gardner K, Mathe S, Sahu S. Leukaemic transformation with romiplostim. Br J Haematol 2012;158:153.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Fenaux P, Sekeres M, . Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010;28:437–444.
   PubMed Web of Science ®Google Scholar
• Basser RL, Rasko JE, Clarke K, . Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997;89:3118–3128.
   PubMed Web of Science ®Google Scholar
• Amgen. Important information concerning updates to the US Nplate^®(romiplostim). July 2011. Available from: www.amgen.com/pdfs/products/NPlate-DHCP-2011-07-27.pdf.pdf
   Google Scholar
• Giagounidis A, Mufti GJ, Kantarjian HM, . Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic patients (Pts) with low or intermediate-1 (Int-1) risk myelodysplastic syndrome (MDS): results of a randomized, double-blind, placebo(PBO)-controlled study. Blood 2011;118(Suppl. 1): Abstract 117.
   Google Scholar
• Oliva E, Latagliata R, Santini V, . Efficacy and safety of eltrombopag for the treatmetn of thrombocytopenia of low and int-1 rish MDS: preliminary results of a prospective, randomized, single-blind placebo-controlled trial. Presented at European Hematology Association 17th Annual Congress. June 2012. Amsterdam, The Netherlands.
   Google Scholar
• Kantarjian H, Giles F, List A, . The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007;109:1705–1714.
   PubMed Web of Science ®Google Scholar
• Houwerzijl EJ, Blom NR, Van Der Want JJL, . Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia 2006;20:1937–1942.
   PubMed Web of Science ®Google Scholar
• Kalina U, Hofmann WK, Koschmieder S, . Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes. Exp Hematol 2000;28:1158–1163.
   PubMed Web of Science ®Google Scholar
• Houwerzijl EJ, Blom NR, van der Want JJL, . Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. Blood 2005;105:3472–3479.
   PubMed Web of Science ®Google Scholar
• Bourgeois E, Caulier MT, Rose C, . Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. Leukemia 2001;15: 950–953.
   PubMed Web of Science ®Google Scholar
• Gilli SCO, de Souza Medina S, de Castro V, . Platelet associated IgG may be related with thrombocytopenia in patients with myelodysplastic syndromes. Leuk Res 2012;36:554–559.
   PubMed Web of Science ®Google Scholar
• Gupta P, LeRoy SC, Luikart SD, . Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 1999;23:953–959.
   PubMed Web of Science ®Google Scholar
• Wattel E, Cambier N, Caulier MT, . Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol 1994;87:205–208.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• Santini V, Fenaux P, Mufti GJ, . Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol 2010;85: 130–138.
   PubMed Web of Science ®Google Scholar
• van den Bosch J, Lübbert M, Verhoef G, . The effects of 5-aza-2’-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 2004;28:785–790.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Greenberg PL, . Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010;116:3163–3170.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Greenberg PL, . Phase II study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010;116:3163–3170.
   PubMed Web of Science ®Google Scholar
• Stasi R, Bosworth J, Rhodes E, . Thrombopoietic agents. Blood Rev 2010;24:179–190.
   PubMed Web of Science ®Google Scholar
• Erickson-Miller CL, Kirchner J, Aivado M, . Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag. Leuk Res 2010;34:1224–1231.
   PubMed Web of Science ®Google Scholar
• Will B, Kawahara M, Luciano JP, . Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009;114:3899–3908.
   PubMed Web of Science ®Google Scholar
• Roth M, Will B, Simkin G, . Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood 2012;120:386–394.
   PubMed Web of Science ®Google Scholar
• Sun H, Tsai Y, Nowak I, . Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res 2012;9:77–86.
   PubMed Web of Science ®Google Scholar